|  | Cancer | Cancer Treatment

Eczema Treatment Options: From OTC to Advanced Systemic Therapies

Eczema Treatment: A Tiered Approach for Lasting Relief

Effective eczema management combines daily skin care, trigger avoidance, and targeted anti-inflammatory therapy tailored to severity, age, and affected areas. This guide outlines current options from over-the-counter to advanced systemic treatments.

1. Foundation: Daily Skin Care (All Severities)

  • Lukewarm baths/showers (5–10 min); gentle, fragrance-free cleanser
  • Pat dry; apply thick moisturizer (cream/ointment) within 3 minutes
  • Reapply moisturizer 2–3×/day; ceramide-rich formulations preferred
  • Humidifier in dry seasons; cotton clothing; short fingernails

2. Over-the-Counter (OTC) Options (Mild Flares)

  • Hydrocortisone 1% cream/ointment: Face, folds, thin skin; ≤2 weeks continuous
  • Colloidal oatmeal baths: Soothes itch and inflammation
  • Oral antihistamines: Sedating (diphenhydramine) at night for sleep; non-sedating (cetirizine) for daytime itch—modest benefit
  • Calamine/pramoxine lotions: Temporary itch relief
  • Barrier repair creams: OTC ceramide-dominant products (CeraVe, Eucerin, Cetaphil)

3. Prescription Topicals (Moderate–Severe)

  • Topical Corticosteroids (TCS): 7 potency classes; match to site/severity. Use "fingertip unit" dosing. Limit high-potency to 2 weeks.
  • Topical Calcineurin Inhibitors (TCI): Tacrolimus 0.03%/0.1%, pimecrolimus 1%. No atrophy; first-line for face, eyelids, folds; proactive maintenance.
  • PDE4 Inhibitor: Crisaborole 2% ointment (≥3 mo); non-steroidal, for mild-moderate AD.
  • Topical JAK Inhibitor: Ruxolitinib 1.5% cream (Opzelura, ≥12 yr); for non-immunocompromised, short-term + maintenance.

4. Phototherapy

  • Narrowband UVB (311–313 nm): 2–3×/week; 60–80% clearance in responders
  • UVA1, PUVA for specific subtypes
  • Requires access to phototherapy unit; eye/genital protection

5. Systemic Therapies (Severe, Refractory)

Traditional Immunosuppressants

  • Cyclosporine: Rapid control; short-term bridge (nephrotoxicity, hypertension)
  • Methotrexate: Weekly; first-line steroid-sparing; monitor LFTs, CBC
  • Azathioprine: TPMT testing; slow onset (8–12 wk)
  • Mycophenolate mofetil: Alternative; GI side effects

Biologics (Targeted, High Efficacy)

  • Dupilumab (IL-4Rα): ≥6 months; q2wk SC; rapid, sustained improvement; conjunctivitis main AE
  • Tralokinumab (IL-13): ≥12 years; q2wk after loading; similar profile

Oral JAK Inhibitors

  • Upadacitinib, Abrocitinib: ≥12 years; once daily; rapid; boxed warnings (infection, thrombosis, malignancy, lipids, cytopenias); require monitoring

6. Pediatric Considerations

  • TCS potency: lowest effective; face/folds: TCI or low-potency TCS
  • Wet-wrap therapy for severe flares (inpatient/outpatient)
  • Biologics approved down to 6 months (dupilumab)
  • Growth monitoring with systemic therapy
  • Family education and psychosocial support essential

7. Lifestyle and Adjunctive Measures

  • Trigger avoidance (identified via history/patch testing)
  • Stress management (CBT, mindfulness)
  • Bleach baths (2×/wk) for recurrent infection
  • Probiotics: limited evidence; discuss with clinician

8. Partnering with Your Clinician

  • Bring photos of flares; track symptoms (POEM, DLQI scores)
  • Request written action plan: daily care, flare escalation, when to call
  • Discuss treatment goals, preferences, cost/access
  • Regular follow-up until controlled, then q3–6mo

With today's expanded armamentarium, most patients can achieve significant clearance and improved quality of life. The key is a structured, proactive partnership with your healthcare team.

Cancer Treatment - Related Articles